endpts.com·May 7, 2026
Blackstone Life Sciences has invested $250 million in Anagram to address complications associated with cystic fibrosis, following a record fundraising effort for its private investment fund.
Blackstone Life Sciences has committed $250 million to Anagram, highlighting a significant investment trend in addressing complications related to cystic fibrosis. For a professional tracking investment signals in biotech, this move underscores the growing financial support for innovative health solutions targeting specific disease complications, potentially signaling opportunities for strategic partnerships or investment in niche biotech areas.